Foundation for Research

The Clayton Foundation for Research is a prominent non-profit medical research organization founded in 1933, dedicated to discovering the causes, prevention, and cures for human diseases. Operating primarily through its commercialization arm, Clayton Biotechnologies, the foundation translates laboratory discoveries into clinical products through strategic patenting and licensing. Its research portfolio spans diverse therapeutic areas including oncology, ophthalmology, and metabolic disorders, utilizing modalities such as monoclonal antibodies and gene therapies. The foundation is well-known for its proprietary DHS mutation technology, which extends the serum half-life of therapeutic antibodies and has been licensed to major pharmaceutical companies like argenx. To date, the foundation's research has contributed to the development of over 16 marketed therapeutic and diagnostic products.